文献速递重症综合管理与镇静镇痛

氟哌啶醇治疗危重症患者谵妄:更新系统评价及荟萃分析与试验序贯分析

Haloperidol for the treatment of delirium in critically ill patients: an updated systematic review with meta-analysis and trial sequential analysis.
PubMed 文献 · Crit Care · 2023-08-26
一句话结论与安慰剂相比,氟哌啶醇可能降低危重症谵妄患者死亡率(RR 0.89,96.7%CI 0.77–1.03,未达统计学显著),严重不良事件/反应无显著差异。

本更新系统评价纳入11项随机临床试验(15项比较,n=2200),其中5项为安慰剂对照,评估氟哌啶醇对危重症谵妄患者死亡率和严重不良事件的影响。与安慰剂相比,死亡率RR为0.89(96.7%CI 0.77–1.03,I²=0%,中等确定性证据),严重不良事件/反应比例RR为0.94(96.7%CI 0.81–1.10,I²=18%,低确定性证据),无谵妄或无昏迷存活天数无差异(中等确定性证据)。作者认为氟哌啶醇可能降低死亡率,但结果未达统计学显著,需更多试验数据提供更高确定性。

要点

  • 与安慰剂相比,氟哌啶醇死亡率RR 0.89(96.7%CI 0.77–1.03,I²=0%,中等确定性证据),未达统计学显著。
  • 与安慰剂相比,严重不良事件/反应比例RR 0.94(96.7%CI 0.81–1.10,I²=18%,低确定性证据),未达统计学显著。
  • 无谵妄或无昏迷存活天数方面,氟哌啶醇与安慰剂无差异(中等确定性证据)。
  • 共纳入11项随机临床试验、15项比较、n=2200,其中5项为安慰剂对照。
  • 作者认为氟哌啶醇可能降低死亡率,但结果未达统计学显著,需更多试验数据提供更高确定性。

适用人群与场景

  • 危重症谵妄患者(纳入随机临床试验的危重症患者人群)

研究设计与关键结果

  • 研究类型:更新系统评价,含荟萃分析与试验序贯分析,纳入11项随机临床试验、15项比较(n=2200),其中5项为安慰剂对照。
  • 主要结局:与安慰剂相比,氟哌啶醇死亡率RR 0.89(96.7%CI 0.77–1.03,I²=0%,中等确定性证据);严重不良事件/反应比例RR 0.94(96.7%CI 0.81–1.10,I²=18%,低确定性证据)。
  • 次要结局:无谵妄或无昏迷存活天数无差异(中等确定性证据);其他次要结局(谵妄严重程度、认知功能、健康相关生活质量)及其他对照比较数据稀疏。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析(含试验序贯分析),遵循Cochrane手册、PRISMA指南及GRADE声明。
  • 死亡率证据确定性:中等;严重不良事件/反应证据确定性:低。
  • 局限:其他次要结局及其他对照比较数据稀疏;结果未达统计学显著,需更多试验数据提供更高确定性。

对床旁实践的改变

  • 作者认为,与安慰剂相比,氟哌啶醇可能降低危重症谵妄患者死亡率,并可能对严重不良事件/反应发生几乎无影响,但结果未达统计学显著,需更多试验数据提供更高确定性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Haloperidol is frequently used in critically ill patients with delirium, but evidence for its effects has been sparse and inconclusive. By including recent trials, we updated a systematic review assessing effects of haloperidol on mortality and serious adverse events in critically ill patients with delirium.

METHODS: This is an updated systematic review with meta-analysis and trial sequential analysis of randomised clinical trials investigating haloperidol versus placebo or any comparator in critically ill patients with delirium. We adhered to the Cochrane handbook, the PRISMA guidelines and the grading of recommendations assessment, development and evaluation statements. The primary outcomes were all-cause mortality and proportion of patients with one or more serious adverse events or reactions (SAEs/SARs). Secondary outcomes were days alive without delirium or coma, delirium severity, cognitive function and health-related quality of life.

RESULTS: We included 11 RCTs with 15 comparisons (n = 2200); five were placebo-controlled. The relative risk for mortality with haloperidol versus placebo was 0.89; 96.7% CI 0.77 to 1.03; I2 = 0% (moderate-certainty evidence) and for proportion of patients experiencing SAEs/SARs 0.94; 96.7% CI 0.81 to 1.10; I2 = 18% (low-certainty evidence). We found no difference in days alive without delirium or coma (moderate-certainty evidence). We found sparse data for other secondary outcomes and other comparators than placebo.

CONCLUSIONS: Haloperidol may reduce mortality and likely result in little to no change in the occurrence of SAEs/SARs compared with placebo in critically ill patients with delirium. However, the results were not statistically significant and more trial data are needed to provide higher certainty for the effects of haloperidol in these patients.

TRIAL REGISTRATION: CRD42017081133, date of registration 28 November 2017.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Andersen-Ranberg NC, Barbateskovic M, Perner A, et al. Haloperidol for the treatment of delirium in critically ill patients: an updated systematic review with meta-analysis and trial sequential analysis. Crit Care. 2023. PMID: 37633991. doi:10.1186/s13054-023-04621-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。